Lumexa Imaging (NASDAQ:LMRI) Stock Price Down 7.6% – Here’s Why

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) dropped 7.6% during trading on Friday . The company traded as low as $11.75 and last traded at $11.7550. Approximately 232,062 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 637,964 shares. The stock had previously closed at $12.72.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial upgraded shares of Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price target on the stock in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Strong Buy” and an average target price of $23.00.

Lumexa Imaging Stock Performance

The business has a 50-day moving average price of $13.86.

Institutional Investors Weigh In On Lumexa Imaging

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. acquired a new position in shares of Lumexa Imaging during the 4th quarter worth about $36,000. Barclays PLC bought a new stake in Lumexa Imaging during the fourth quarter worth about $133,000. Sandia Investment Management LP bought a new stake in Lumexa Imaging during the fourth quarter worth about $185,000. Hudson Bay Capital Management LP acquired a new position in Lumexa Imaging during the fourth quarter valued at approximately $237,000. Finally, Oxford Asset Management LLP acquired a new position in Lumexa Imaging during the fourth quarter valued at approximately $670,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).